Previous 10 | Next 10 |
Gainers: ArcLight Clean Transition (ACTCU) +80%.VOXX International (VOXX) +47%.BIOLASE (BIOL) +43%.Dolphin Entertainment (DLPN) +41%.ENGlobal (ENG) +39%.Zomedica (ZOM) +39%.IRIDEX (IRIX) +34%.AcelRx Pharmaceuticals (ACRX) +28%.La Jolla Pharmaceutical (LJPC) ...
Gainers: Zomedica (ZOM) +36%, IRIDEX (IRIX) +34%, Biomerica (BMRA) +32%, La Jolla Pharmaceutical (LJPC) +29%, Tyme Technologies (TYME) +15%.Losers: Avinger (AVGR) -17%, TransEnterix (TRXC) -16%, PolarityTE (PTE) -14%, ...
La Jolla Pharmaceutical (LJPC) +62% on exclusive licensing agreement with PAIONVOXX International (VOXX) +56% after posting strong sales growth.T2 Biosystems (TTOO) +33% after the company says its T2SARS-CoV-2 Panel is capable of detecting multiple variants of the COVID-19 viru...
La Jolla Pharmaceutical (LJPC) surged 34.5% in premarket trade after it entered into an exclusive licensing agreement with PAION and its wholly owned subsidiary for GIAPREZA (angiotensin II) and XERAVA (eravacycline) in the European Economic Area, U.K. and Switzerland.Unde...
La Jolla to receive upfront cash payment of $22.5 million plus potential commercial milestone payments of up to $109.5 million and double-digit tiered royalty payments La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercializa...
La Jolla has lost nearly 90% of its market capitalization in recent years. The low revenue figures La Jolla has been reporting in recent years from its main drug, Giapreza, are heavily penalizing the share price. Barring surprise in the future sales figures for both drugs, I don't...
La Jolla Pharmaceutical (LJPC): Q3 GAAP EPS of -$0.43 beats by $0.11.Revenue of $9.07M (+58.8% Y/Y) beats by $2.57M.Shares -3.70% AH.Press Release For further details see: La Jolla Pharmaceutical EPS beats by $0.11, beats on revenue
La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and nine months ended Septe...
La Jolla Pharmaceutical (NASDAQ: LJPC ) says Lakhmir Chawla, M.D., Chief Medical Officer gave notice of his intent to resign effective October 2. More news on: La Jolla Pharmaceutical Company, Healthcare stocks news, Stocks on the move, Read more ...
Insider buying decreased significantly last week with insiders purchasing $31.16 million of stock compared to $111.24 million in the week prior. Selling also decreased significantly with insiders selling $749.85 million of stock last week compared to $2.46 billion in the week prior. Sell/Bu...
News, Short Squeeze, Breakout and More Instantly...
La Jolla Pharmaceutical Company Company Name:
LJPC Stock Symbol:
NASDAQ Market:
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of L...
The biotech investment sector has always been its own market, very distinct from other sectors. So it was no surprise that when most sectors turned slowly upward after the pandemic-inspired crash, Biotech (XBI) rose 164%, exceeding the overall market (SPY) performance by triple digits. Then, a...